|
Number of patients
|
110
|
47
|
63
|
|
Females, n (%)
|
40 (36.4)
|
18 (38.3)
|
22 (34.9)
|
|
Age, years, mean ± SD
|
51.7 ± 1.3
|
53.0 ± 1.3
|
49.6 ± 1.3
|
|
Schooling
|
|
Primary school, n (%)
|
8 (7.3)
|
4 (8.5)
|
4 (6.3)
|
|
Middle school, n (%)
|
45 (40.9)
|
18 (38.3)
|
27 (42.9)
|
|
Secondary school, n (%)
|
36 (32.7)
|
17 (36.2)
|
19 (30.2)
|
|
University, n (%)
|
21 (19.1)
|
8 (17)
|
13 (20.6)
|
|
Social status
|
|
Living with parents and family, n (%)
|
15 (13.6)
|
6 (12.8)
|
9 (14.3)
|
|
Living alone, n (%)
|
16 (14.5)
|
7 (14.9)
|
9 (14.3)
|
|
Living with partner and family, n (%)
|
71 (64.5)
|
29 (61.7)
|
42 (66.7)
|
|
Others, n (%)
|
8 (7.3)
|
5 (10.6)
|
3 (4.8)
|
|
Full- or part-time employed, n (%)
|
76 (69.1)
|
29 (61.7)
|
47 (74.6)
|
|
Smoking, current, n (%)
|
17 (15.5)
|
5 (10.6)
|
12 (19)
|
|
HLA-B27 positivity, n (%)
|
58 (52.7)
|
22 (46.8)
|
36 (57.1)
|
|
Psoriasis, n (%)
|
58 (50.7)
|
26 (55.3)
|
32 (50.8)
|
|
Uveitis, n (%)
|
7 (6.4)
|
5 (10.6)
|
2 (3.2)
|
|
Disease duration (years), mean ± SD
|
15.3 ± 9.7
|
15.7 ± 10
|
15 ± 9.5
|
|
Mechanism of action of current b/tsDMARD
|
|
TNF inhibitors, n (%)
|
85 (77.3)
|
40 (85.1)
|
45 (71.4)
|
|
IL-12/23 inhibitors, n (%)
|
9 (8.2)
|
1 (2.1)
|
8 (12.7)
|
|
IL-17 inhibitors, n (%)
|
14 (12.7)
|
6 (12.8)
|
8 (12.7)
|
|
PDE4 inhibitors, n (%)
|
2 (1.8)
|
0 (0)
|
2 (3.2)
|
|
Duration of b/tsDMARD treatment overall, years, mean ± SD
|
5 ± 4.1
|
5.8 ± 4.5
|
4.5 ± 3.8
|
|
Low-dose b/tsDMARD treatment, n (%)
|
28 (25.5)
|
11 (23.4)
|
17 (27)
|
|
b/tsDMARD naïve patients, n (%)
|
81 (73.6)
|
37 (78.7)
|
44 (69.8)
|
|
No. of b/tsDMARD treatments, mean ± SD
|
1.5 ± 0.9
|
1.3 ± 0.7
|
1.6 ± 1.1
|
|
Steroid, n (%)
|
9 (8.2)
|
1 (2.1)
|
8 (12.7)
|
|
NSAID, n (%)
|
76 (69.1)
|
30 (63.8)
|
46 (73)
|
|
csDMARD, n (%)
|
14 (12.7)
|
5 (10.6)
|
9 (14.3)
|
|
Concomitant treatments, n (%)
|
62 (56.4)
|
27 (57.4)
|
35 (55.6)
|
|
Distance from clinic, km, mean ± SD
|
36.1 ± 47.2
|
31.1 ± 34.2
|
39.7 ± 54.9
|
